Zum Hauptinhalt springen
| Hans-Günter Meyer-Thompson | International

USA. To aid addiction treatment, lawmakers tell DEA to back off buprenorphine enforcement - The agency has Suboxone on its Suspicious Order Reporting System

USA. To aid addiction treatment, lawmakers tell DEA to back off buprenorphine enforcement - The agency has Suboxone on its Suspicious Order Reporting System

Two Democratic lawmakers are pushing the Drug Enforcement Administration to take a more lax approach to regulating buprenorphine, a medication used to treat opioid addiction. 

“Bupe,” also known by the brand name Suboxone, is one of just two medications currently approved to treat opioid cravings and withdrawal. And though it is associated with a 38% reduction in risk of opioid death, it remains stigmatized because it is chemically an opioid — and, accordingly, highly scrutinized by the DEA. (Stat News, USA, 03.10.2024)

https://www.statnews.com/2024/10/03/opioid-addiction-buprenorphine-dea-monitoring